secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001689375-23-000017
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada reports FY2022 net loss $94.6M; Vertex deal adds $224M upfront, extends cash into 2H 2025
--------------------------------------------------------------------------------

- Net loss $24.6M Q4, $94.6M FY2022; R&D expenses $15.7M Q4, $66.6M FY2022.
- Cash, equivalents & securities $188.7M at Dec 31, 2022; runway extended into 2H 2025 after Vertex deal.
- Vertex collaboration closed Feb 2023: $224M upfront + $26M equity; up to $485M milestones plus royalties.
- FDA clinical hold on ENTR-601-44 IND; company working to resolve, aiming for healthy volunteer trial in 2023.
- Selected ENTR-601-45 for Duchenne exon 45 skipping; IND planned for Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937523000017/0001689375-23-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937523000017/trda-20230306.htm
  HTML page:      https://secwatch.observer/filing/0001689375-23-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer